Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb CofiledCriticalBristol Myers Squibb Co
Publication of AR132628A1publicationCriticalpatent/AR132628A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Se describen compuestos de fórmula (1) o estereoisómeros, tautómeros o sales de los mismos, en los que cada R es independientemente H o D. También se describen métodos de uso de dichos compuestos para disminuir los niveles de proteínas IKZF1-4; y composiciones farmacéuticas que comprenden el compuesto. Los compuestos son útiles en el tratamiento de infecciones virales y trastornos proliferativos, tales como el cáncer.Disclosed are compounds of formula (1) or stereoisomers, tautomers, or salts thereof, wherein each R is independently H or D. Also disclosed are methods of using such compounds to decrease levels of IKZF1-4 proteins; and pharmaceutical compositions comprising the compound. The compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
DERIVATIVES OF 8- [6- [3- (AMINO) PROPOXI] -3-PIRIDIL] 1-ISOPROPILIMIDAZO [4,5-C] QUINOLIN-2-ONA AS SELECTED MODULATORS OF THE MUTED TELANGIECTASIA ATAXIA KINASE (ATM) FOR THE CANCER TREATMENT